Ranbaxy (SA) (Pty), a wholly owned subsidiary of Ranbaxy Laboratories, opened a new manufacturing facility, Be-Tabs Pharmaceuticals manufacturing plant at Roodepoort, Johannesburg, South Africa.This will be Ranbaxy?s second manufacturing facility in South Africa and the third in the African continent.
The new facility, built with an investment of $30 million will manufacture analgesics, cold, cough and flu preparations, anti-histamines, anti-hypertensives, CNS drugs, vitamins and minerals as well as a comprehensive range of over-the-counter medication. The products manufactured will comprise tablets and hard gelatin capsules that will be supplied to current registered regions, the company said in a statement.
?We were the first Indian pharmaceutical company to set up a manufacturing facility in Nigeria. Over the years, we have established a strong presence in 43 of the 54 African countries with the aim of providing quality medicines and improving access. The new facility emphasises our commitment towards Africa and South Africa in particular,” Arun Sawhney, managing director, Ranbaxy said.
The design of the new facility is determined by the current tablet and capsule production requirements and the plant is capable of producing approximately 1.75 billion units and packaging of 2.0 billion units, annually. Saxen van Coller, CEO, Ranbaxy SA (Pty) said, ?The capacity to manufacture locally will meet the South African government?s intention to strengthen the local pharmaceutical manufacturing industry.?